The remdesivir and control group were balanced regarding age, sex, CCI, WHO COVID-19 severity, and Eastern Cooperative Oncology Group (ECOG) functional status, C-reactive protein (CRP), ferritin, and procalcitonin on admission, and MV and HFOT support during hospital stay, as per the matching procedure (P > 0.05 for all comparisons). Here, CRP is linked to COVID-19.